Semaglutide improved health, reduced aging-related changes, and extended lifespan in older female mice, sometimes outperforming caloric restriction.
People using Wegovy, a GLP-1 agonist approved by the US Food and Drug Administration for weight loss, may be about five times at risk of developing ‘eye stroke’ that can lead to sight loss, compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results